

Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

NCT06036004

Status	RECRUITING
Phase	Phase 2
Sponsor	University Hospital, Basel, Switzerland
Enrollment	112 participants

Key Eligibility Criteria

Inclusion (3)

- Adult patients with a confirmed diagnosis of central diabetes insipidus based on accepted criteria
- Heightened anxiety levels (STAI - Trait subscale ≥ 39 score points) or alexithymia levels (impaired ability to identify and describe feelings; TAS-20 total ≥ 52 score points)
- Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies.

Exclusion (7)

- Participation in a trial with investigational drugs within 30 days
- Active substance use disorder within the last six months
- Consumption of alcoholic beverages >15 drinks/week
- Current or previous psychotic disorder (e.g., schizophrenia spectrum disorder)
- Pregnancy and breastfeeding within the last eight weeks
- ... and 2 more (see full listing online)

Locations (2 total)

Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands
University Hospital Basel, Department of Endocrinology, Diabetes & Metabolism, Basel, Switzerland